Jun 12, 2025
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
May 01, 2025
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Apr 25, 2025
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Mar 31, 2025
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference
Feb 28, 2025
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress
Feb 13, 2025
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
Jan 12, 2025
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
Dec 18, 2024
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Oct 30, 2024
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Oct 16, 2024
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
Aug 01, 2024
Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Jul 18, 2024
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
May 30, 2024
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
May 23, 2024
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
May 06, 2024
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Apr 11, 2024
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
Apr 04, 2024
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 06, 2024
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 15, 2024
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results